技术文章您现在的位置:首页 > 技术文章 > BioXCell热销产品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

BioXCell热销产品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

更新时间:2024-01-23   点击次数:128次

BioXCell热销产品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

 

产品描述:

9D9-CP008单克隆抗体是原始9D9单克隆抗体的重组嵌合型抗体。可变结构域序列与原始9D9克隆号相同,但是恒定区序列已经从小鼠IgG2b变为小鼠IgG2a。9D9-CP008单克隆抗体在Fc片段中也含有LALA-PG突变,使其无法与内源性Fcγ受体结合。

 

9D9-CP008单克隆抗体能与小鼠CTLA-4(细胞毒性T淋巴细胞抗原-4)反应,CTLA-4也称为CD152。CTLA-4是一种33 kDa的细胞表面受体,由属于免疫球蛋白超家族CD28家族的Ctla4基因编码。CTLA-4在活化的T淋巴细胞和B淋巴细胞上表达。CTLA-4在结构上类似于T细胞共刺激蛋白CD28,两种分子都与B7家族成员B7-1 (CD80)和B7-2 (CD86)结合。在与配体结合时,CTLA-4负调节细胞介导的免疫反应。CTLA-4在诱导和/或维持免疫耐受、胸腺细胞发育和保护性免疫调节中起作用。CTLA-4在免疫下调中的关键作用已经在CTLA-4缺陷小鼠中得到证实,这些小鼠在3-5周龄时由于淋巴增生性疾病的发展而死亡。CTLA-4目前是肿瘤免疫治疗中的热门免疫检查点靶点之一。

 

产品详情:

产品名称

RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)/欣博盛生物

产品货号

CP008

产品规格

1mg

反应种属

Mouse

克隆号

9D9-CP008

同种型

Mouse IgG2b(switched from mouse IgG2a)

免疫原

Not available or unknown

实验应用

in vivo CTLA-4 neutralization*

Western blot*

*Reported for the original mouse IgG2b 9D9 antibody

产品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

纯度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

无菌处理

0.2 µm filtration

纯化方式

Protein A

分子量

150 kDa

小鼠病原检测

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存条件

抗体原液保存在4°C,不能冷冻保存。

推荐抗体稀释液

InVivoPure pH 7.0 Dilution Buffer(货号IP0070)

 

该产品自上市已被多篇SCI文献引用,品质有保证,以下是部分已发表的文献引用:

应用

文章

体内CTLA-4中和

(in vivo CTLA-4 

neutralization)

1. Dai, M., et al. (2015). 'Curing mice with large tumors by locally 

delivering combinations of immunomodulatory antibodies' 

Clin Cancer Res 21(5): 1127-1138.

2. Zippelius, A., et al. (2015). 'Induced PD-L1 expression mediates 

acquired resistance to agonistic anti-CD40 treatment' Cancer Immunol 

Res 3(3): 236-244.

3. Redmond, W. L., et al. (2014). 'Combined targeting of costimulatory 

(OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T 

cells capable of driving robust antitumor immunity' Cancer Immunol 

Res 2(2): 142-153.

4. Condamine, T., et al. (2014). 'ER stress regulates myeloid-derived 

suppressor cell fate through TRAIL-R-mediated apoptosis' J Clin Invest 

124(6): 2626-2639.

5. Muller, P., et al. (2014). 'Microtubule-depolymerizing agents used in 

antibody-drug conjugates induce antitumor immunity by stimulation of 

dendritic cells' Cancer Immunol Res 2(8): 741-755.

6. Bulliard, Y., et al. (2013). 'Activating Fc gamma receptors contribute 

to the antitumor activities of immunoregulatory receptor-targeting 

antibodies' J Exp Med 210(9): 1685-1693.

 

 

 

BioXCell热销产品--RecombiMAb anti-mouse CTLA-4 (CD152) (LALA-PG)

更多产品详情请联系 BioXCell 中国授权代理——欣博盛生物